Search the Newsreel

Bioceres Crop Solutions Corp. Revenue Breakdown – FWB:0G4

Bioceres Crop Solutions Corp. (FWB:0G4) generated €284.64 million in revenue last year. Its Crop Protection segment was the top performer, contributing €154.42 million, while Argentina was the largest regional contributor at €196.57 million. These figures indicate a notable decrease in overall revenue and the …

BTAI|BioXcel Therapeutics Inc|Price:0.870|Chg%:+0.022

BioXcel Therapeutics Inc (BTAI) is a biopharmaceutical company utilizing AI to develop neuroscience and immuno-oncology medicines. Despite a recent weak stock market performance, the company's fundamentals are stable, growth potential is high, and institutional ownership is very high. Analysts have rated BTAI as a …

Bioceres Crop Solutions (BIOX) Q1 2025 earnings summary

Bioceres Crop Solutions reported a 20% year-over-year revenue decline to $93.3 million for Q1 2025, primarily due to drought in Argentina, yet saw growth in North America and Brazil. The net loss widened to $5.3 million, and Adjusted EBITDA fell by 48%. The company …

Bioceres Crop Solutions (BIOX) Registration Filing Summary

This article provides a summary of Bioceres Crop Solutions' (BIOX) Registration Filing on December 16, 2025. It details the company's business model, product portfolio, risk factors, and market opportunities in the agricultural solutions sector. The summary also lists recent financial events and their impact …

BioXcel Therapeutics (BTAI) Investor update Summary

BioXcel Therapeutics (BTAI) is preparing for the potential Q1 2027 launch of IGALMI for at-home treatment of acute agitation, targeting a significant market with no currently FDA-approved competitors. The company highlights high unmet need, strong physician and patient interest, and a favorable payer outlook …

BioXcel Therapeutics (BTAI) Q1 2026 earnings summary

BioXcel Therapeutics reported a net loss of $12.7 million for Q1 2026, an increase from Q1 2025, despite a slight rise in IGALMI® sales. The company achieved a significant regulatory milestone with FDA acceptance of its sNDA for IGALMI® for at-home use. However, BioXcel …

Bioceres Crop Solutions (BIOX) Edges Higher Amid Low-Price Dynamics - Strong Buy Stocks

BIOX Q2 2026 Earnings: EPS Misses Estimates Sharply, Shares Tumble 8.4% - Earnings Revision Report

Bioxyne Limited Applies for Quotation of New Shares Following Option Conversions in June 2026

BTAI Forecast — Price Target — Prediction for 2027

Bioceres Crop Solutions updates earnings provision and reports court ruling

Form 6K Bioceres Crop Solutions Corp For: 22 June By Investing.com

BIOX Q1 2026 Earnings: EPS Misses Estimates Sharply, Stock Declines Over 7% - Subscription Growth Report

What Makes BioXcel Therapeutics (BTAI) a New Buy Stock

Bioceres Crop (NASDAQ: BIOX) unit swaps US$42.7M in notes at 86% take-up

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

Bioceres Crop Solutions Reports Q3 FY2026 Revenue Decline as Seeds Transition and Pro Farm Foreclosure Weigh on Results

Earnings call transcript: Bioceres Crop’s Q3 2026 struggles amid restructuring

Bioxyne (ASX:BXN) Advances European Expansion Strategy With Multi-Year German Contract

Bioceres Crop (BIOX) Reports Q3 Loss, Misses Revenue Estimates

Bioceres Crop Solutions Reports Fiscal Third Quarter 2026 Financial and Operational Results

BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?

If EPS Growth Is Important To You, Bioxyne (ASX:BXN) Presents An Opportunity

BioXcel says at-home agitation drug could target 86M yearly episodes

BioXcel Therapeutics Stock Soars Amid New Drug Approval Speculation

Bioxyne Boosts FY26 Outlook on Strong Performance and International Growth

Why Investors Shouldn't Be Surprised By Bioxyne Limited's (ASX:BXN) 30% Share Price Surge

Investors Don't See Light At End Of Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Tunnel And Push Stock Down 54%

What Analysts Think Is Changing The Story For BioXcel Therapeutics Now

Is Bioceres Crop Solutions (NASDAQ:BIOX) A Risky Investment?

Bioceres Crop Solutions Corp (BIOX) Q1 2026 Earnings Call Highlights: Navigating Revenue ...

Bioxyne upgrades FY25 outlook by $3m to $28m on rising demand for psychedelic drug therapies

Individual investors among Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) largest stockholders and were hit after last week's 22% price drop

Bioceres Crop Solutions Corp (BIOX) Q4 2025 Earnings Call Highlights: Navigating Challenges ...

BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments

BioXcel Therapeutics, Inc. Share Price Live Today – NASDAQ:BTAI Stock Price, Chart, News, History